General
Preferred name
DASATINIB
Synonyms
KIN001-005 ()
Sprycel, BMS-354825-03, BMS-354825 ()
BMS-354825 ()
Sprycel ()
BMS-354825 Monohydrate ()
BMS-354825 HCl ()
Dasatinib (BMS-354825) ()
Dasatinib Monohydrate ()
DASATINIB ANHYDROUS ()
Dasatinib (hydrochloride) ()
Dasatinib (monohydrate) ()
BMS-354825 (hydrochloride) ()
BMS-354825 (monohydrate) ()
Dasatinib hydrochloride ()
DasatinibSprycelBMS-354825N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate ()
BMS-354825 HYDRATE ()
BMS-354825-03 ()
DASATINIB ACCORDPHARMA ()
DASATINIB HYDRATE ()
NSC-759877 ()
DASATINIB LAURYLSULFATE ()
Dasatinib-d8 ()
Dasatinib accordpharma ()
Dasatinib accord ()
Dasatinib (anhydrous) ()
Dasatinib accord healthcare ()
Dasatinib monohydrate ()
Dasatinib monolauryl sulfate ()
C078D ()
Vysentri ()
Dasatanib ()
DASATINIB (ANHYDROUS) ()
DASATINIB ACCORD ()
P&D ID
PD003446
CAS
302962-49-8
863127-77-9
854001-07-3
1132093-70-9
Tags
available
obsolete probe
drug
drug candidate
Approved by
EMA
FDA
First approval
2006
Drug indication
B-cell acute lymphoblastic leukemia
Middle East Respiratory Syndrome (MERS)
Multiple myeloma
Neoplasm
Severe acute respiratory syndrome (SARS)
Chronic myelogenous leukaemia
Chronic lymphocytic leukemia
Parkinson disease
Drug Status
approved
investigational
Max Phase
1.0
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Dasatinib is a Type-1 kinase inhibitor and was first approved by the FDA in 2006.
A combination of dasatinib and has been investigated in animal models for senolytic activity . Senolytic agents are intended to reduce the abundance of senescent cells as a mechanism to treat age-related diseases, reduce frailty and extend healthy lifespan . (GtoPdb)
A combination of dasatinib and has been investigated in animal models for senolytic activity . Senolytic agents are intended to reduce the abundance of senescent cells as a mechanism to treat age-related diseases, reduce frailty and extend healthy lifespan . (GtoPdb)
DESCRIPTION
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib also induces apoptosis and autophagy.
PRICE
29
DESCRIPTION
Dasatinib (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib hydrochloride also induces apoptosis and autophagy.
PRICE
29
DESCRIPTION
Dasatinib (BMS-354825) monohydrate is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib monohydrate inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively[1]. Dasatinib monohydrate also induces apoptosis and autophagy.
PRICE
29
DESCRIPTION
inhibitor of SRC, YES1, EPHA2, c-KIT, and LCK
(Informer Set)
DESCRIPTION
For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
(PKIDB)
DESCRIPTION
Dynamin-related GTPase DRP1 partial inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Dasatinib is a tyrosine kinase inhibitor used for the treatment of lymphoblastic or chronic myeloid leukemia with resistance or intolerance to prior therapy.
(Enamine Bioactive Compounds)
DESCRIPTION
Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16/30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Dasatinib hydrochloride is a potent and dual Abl/ Src inhibitor. It inhibits c-Kit (WT)/c-Kit (D816V).
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride hydrochloride also induces Apoptosis and Autophagy.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, PDGFR, ephrin receptors, Src, c-Kit, and other Src-family kinases (LCK, HCK, FYN, and others)
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
283
Organisms
5
Compound Sets
41
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Obsolete Compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
86
Molecular Weight
487.16
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
3
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
3
cLogP
3.31
TPSA
106.51
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
6.0
QED
0.47
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
EPHA2
KIT
LCK
SRC
YES1
ABL, SRC, KIT, PDGFR
ABL
c-Kit (D816V)
c-Kit (wt)
ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1
Bcr-Abl/Src inhibitor
Apoptosis related,Autophagy,Bcr-Abl,c-Kit,Src
Bcr-Abl,c-Kit,Src
Bcr-Abl,kit,Src
ABL1
PDGFRB
ABL2
Fyn
Compound status
FDA
Pathway
ABL signaling
Angiogenesis
Apoptosis
Autophagy
Cytoskeletal Signaling
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Targets
ABL1,SRC
Primary Target
Src Kinases
MOA
Bcr-Abl
c-Kit
Src
Inhibitor
Src Kinase Inhibitors
Inhibitors of Signal Transduction Pathways
Bruton's Tyrosine Kinase (BTK) Inhibitors
Bcr-Abl Kinase Inhibitors
Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, SRC inhibitor, tyrosine kinase inhibitor
Member status
virtual
Indication
chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)
Therapeutic Indication
Anticancer
Therapeutic Class
Anticancer Agents
Antiviral Agents
VGSC Target
Nav1.5
Solubility
Soluble in DMSO (Slightly, Sonicated), Methanol (Slightly, Sonicated)
Recommended Cell Concentration
None
Source data
